Article

New devices and technology take IOP monitoring to next level

Though monitoring IOP in patients with glaucoma is important, it is fairly well established that the higher the IOP, the greater the chance of glaucoma disease progression. Ophthalmologists now need to track peak IOPs, daily variability of pressure, patient body position, and effects of therapy, said L. Jay Katz, MD, director of Glaucoma Services, Wills Eye Institute, Philadelphia, and professor of ophthalmology, Thomas Jefferson University,

San Francisco-Though monitoring IOP in patients with glaucoma is important, it is fairly well established that the higher the IOP, the greater the chance of glaucoma disease progression. Ophthalmologists now need to track peak IOPs, daily variability of pressure, patient body position, and effects of therapy, said L. Jay Katz, MD, director of Glaucoma Services, Wills Eye Institute, Philadelphia, and professor of ophthalmology, Thomas Jefferson University,

Sleep laboratory studies show IOP is higher at night, especially between 9 p.m. and 3 a.m. and when patients are supine. Response to treatment, body position (upside down), and whether the patient plays a wind instrument all have been shown to influence IOP, he noted.

Ultimately, for better patient care, ophthalmology needs better IOP assessment tools. The future of IOP assessment includes home tonometers and telemetry, said Dr. Katz, who summarized the new field of IOP monitoring devices for attendees at the Glaucoma 360 CME Symposium.

He cited a tonometer (Icare Finland) in use in the European Union that has been tested in humans with 75% of the study cohort trained to take reasonably good measurements after education and training. The device requires no topical anesthetic and has a disposable tip. However, it cannot monitor the patient during sleep. 

One contact lens (Sensimed Triggerfish) measures corneal curvature and not mm Hg. However, the device takes a measurement every 90 seconds storing up to 144 points of data over 24 hours that can be converted to IOP. 

Implantable devices are under development, supported by in vitro and in vivo telemetry study data. One such implant being tested in Germany measures a true IOP and is programmable over a 24-hour period. This device comes in two formations-the ARGOS-IO (intraocular) and ARGOS-EO (extraocular)-for monitoring in various disorders. 

Companies also are developing wireless remote applications to measure direct IOP. Patients could then self-record IOP on their smartphones, forward these measurements to their physicians, who would collect this data into electronic patient files. 

Future telemetry tools will allow at-home eye monitoring, which would revolutionize patient care with quicker adjustments to therapy, fewer office visits, detection of treatment non-adherence, and engagement of patients in their own care.  

For more articles in this issue of Ophthalmology Times’ Conference Briefclick here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.